866 Participants Needed

Imlunestrant + Abemaciclib for Breast Cancer

(EMBER-3 Trial)

Recruiting at 395 trial locations
Tm
Overseen ByThere may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Eli Lilly and Company
Must be taking: Aromatase inhibitors
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, it mentions that participants should have progressed on certain treatments, which might imply changes in medication. It's best to discuss your specific situation with the trial team.

What data supports the effectiveness of the drug combination Imlunestrant and Abemaciclib for breast cancer?

Research shows that Abemaciclib, when used with other treatments like fulvestrant or letrozole, significantly improves progression-free survival in women with hormone receptor-positive, HER2-negative advanced breast cancer. This suggests that Abemaciclib is effective in treating similar types of breast cancer.12345

Is the combination of Imlunestrant and Abemaciclib safe for humans?

Abemaciclib, when used with other treatments for breast cancer, has shown a generally tolerable safety profile, with common side effects including diarrhea and low white blood cell counts. Most side effects were mild, but some, like neutropenia (low levels of a type of white blood cell), were more severe in a smaller number of patients.15678

What makes the drug combination of Imlunestrant and Abemaciclib unique for breast cancer treatment?

The combination of Imlunestrant and Abemaciclib is unique because it pairs a novel estrogen receptor degrader (Imlunestrant) with a cyclin-dependent kinase 4 and 6 inhibitor (Abemaciclib), which together target hormone receptor-positive, HER2-negative breast cancer by both blocking estrogen's effects and inhibiting cancer cell growth.14579

Research Team

C1

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

This trial is for postmenopausal women with advanced breast cancer that's ER+ and HER2-. They should have seen their cancer progress after aromatase inhibitor treatment, possibly combined with a CDK4/6 inhibitor. Participants must be able to take pills, have measurable disease or bone-only disease, and be in good physical condition (ECOG 0-1). They can't join if they've had certain prior treatments like chemotherapy or specific inhibitors, have severe brain metastasis, visceral crisis, lung complications from cancer spread, or serious medical conditions.

Inclusion Criteria

My breast cancer is ER+ and HER2-, and has spread beyond the breast.
My cancer progressed after treatment with an aromatase inhibitor and possibly a CDK4/6 inhibitor.
My kidney, blood, and liver functions are all within normal ranges.
See 7 more

Exclusion Criteria

I have previously been treated with specific cancer therapies, excluding early-stage chemotherapy.
My cancer has spread to my organs, lungs, or brain/spinal cord linings.
Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive imlunestrant, investigator's choice of endocrine therapy, or imlunestrant plus abemaciclib

Up to 3 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 2 years

Open-label extension (optional)

Participants may opt into continuation of treatment long-term

Long-term

Treatment Details

Interventions

  • Abemaciclib
  • Exemestane
  • Fulvestrant
  • Imlunestrant
Trial OverviewThe study tests the effectiveness of Imlunestrant against standard hormone therapy and combines Imlunestrant with Abemaciclib versus Imlunestrant alone in treating ER+, HER2- advanced breast cancer. The goal is to see which treatment works better for patients whose cancer has spread. Participation could last up to five years.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: Imlunestrant plus AbemaciclibExperimental Treatment2 Interventions
Imlunestrant plus abemaciclib administered orally.
Group II: ImlunestrantExperimental Treatment1 Intervention
Imlunestrant administered orally.
Group III: Investigator's Choice of Endocrine TherapyActive Control2 Interventions
Investigator's choice of exemestane administered orally or fulvestrant administered intramuscularly (IM). See local approved label for additional instructions.

Exemestane is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Aromasin for:
  • Early breast cancer
  • Advanced breast cancer
🇺🇸
Approved in United States as Aromasin for:
  • Early breast cancer
  • Advanced breast cancer
🇨🇦
Approved in Canada as Aromasin for:
  • Early breast cancer
  • Advanced breast cancer
🇯🇵
Approved in Japan as Aromasin for:
  • Early breast cancer
  • Advanced breast cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials
2,708
Recruited
3,720,000+
Dr. Daniel Skovronsky profile image

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks profile image

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University

Findings from Research

Abemaciclib combined with endocrine therapy (ET) significantly improves quality-adjusted life years (QALYs) in patients with high-risk hormone receptor positive, HER2-negative early breast cancer, with an increase of 0.99 QALYs compared to ET alone.
The treatment is considered cost-effective in Italy, with an incremental cost-effectiveness ratio of €22,651 per QALY gained, and a 99% likelihood of being cost-effective at a threshold of €30,000 per QALY.
Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy.Davie, A., Traoré, S., Giovannitti, M., et al.[2023]
In the FLIPPER trial, the combination of palbociclib and fulvestrant significantly improved progression-free survival (PFS) in postmenopausal women with HR+/HER2- advanced breast cancer compared to placebo and fulvestrant.
Patient-reported outcomes indicated that while global health status and quality of life (QoL) were maintained during treatment with palbociclib/fulvestrant, the time to deterioration in QoL was longer with placebo/fulvestrant, suggesting that palbociclib/fulvestrant is a beneficial treatment option.
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.Tibau, A., Martínez, MT., Ramos, M., et al.[2023]
In the MONARCH 2 study, abemaciclib combined with fulvestrant significantly improved progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor positive, HER2-negative advanced breast cancer, showing consistent benefits across both first-line and second-line treatment groups.
The most substantial benefits were seen in patients with primary resistance to endocrine therapy and those with visceral disease, indicating that abemaciclib may be particularly effective for these subgroups.
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer.Neven, P., Johnston, SRD., Toi, M., et al.[2022]

References

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy. [2023]
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. [2023]
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer. [2022]
First-Line Abemaciclib Effective in ER+ Breast Cancer. [2019]
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. [2022]
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. [2022]
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. [2022]
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. [2023]
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer. [2023]